Asthma and COPD - The C/EBP connection

Open Respiratory Medicine Journal

Volumn 6, Issue 1, 2012, Pages 1-13

  Miglino, Nicola ^a   Roth, Michael ^a   Tamm, Michael ^a   Borger, Peter ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Airway inflammation; Airway wall remodelling; Asthma; CCAAT enhancer binding proteins; COPD

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; CCAAT ENHANCER BINDING PROTEIN EPSILON; CCAAT ENHANCER BINDING PROTEIN GAMMA; CCAAT ENHANCER BINDING PROTEIN ZETA; LITHIUM CHLORIDE; MESSENGER RNA; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AIRWAY REMODELING; ASTHMA; CEBPA GENE; CEBPB GENE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DERMATOPHAGOIDES; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE; HUMAN; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; REVIEW; RNA TRANSLATION; SMOKING; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER;

EID: 84860698311     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401206010001     Document Type: Review

References (210)

1. Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Respir Med 2007; 101: 378-388.
2. Global Initiative for asthma (GINA), Report, 2006. Available at: http://www.ginasthma.org/Guidelineitem.asp?l1=2&l2=1&intId=1558
3. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008; 38: 872-897.
4. Reed CE. The natural history of asthma. J Allergy Clin Immunol 2006; 118: 543-548.
5. [No Author Listed]. Asthma: still more questions than answer. Lancer 2008; 372: 1009.
6. Holloway JW, Beghé B, Holgate ST. The genetic basis of atopic asthma. Clin Exp Allergy 1999; 29: 1023-1032.
7. Wiesch DG, Meyers DA, Bleecker ER. Genetics of asthma. J Allergy Clin Immunol 1999; 104: 895-901.
8. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-1260.
9. Postma DS, Bleecker ER, Amelung PJ, et al. Genetic susceptibility to asthma--bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995; 333: 894-900.
10. Laprise C, Sladek R, Ponton A, Bernier M, Hudson TJ, Laviolette M. Functional classes of bronchial mucosa genes that are differentially expressed in asthma. BMC Genomics 2004; 5: 21.
11. Horwood LJ, Fergusson DM, Shannon FT. Social and familial factors in the development of early childhood asthma. Pediatrics 1985; 75: 859-868.
12. Wahn U, Lau S, Bergmann R, et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. J Allergy Clin Immunol 1997; 99: 763-769.
13. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990; 323: 502-507.
14. Hogaboam CM, Carpenter KJ, Schuh JM, Buckland KF. Aspergi-llus and asthma--any link? Med Mycol 2005; 43: S197-S202.
15. Huss K, Adkinson NF Jr, Eggleston PA, Dawson C, Van Natta ML, Hamilton RG. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol 2001; 107: 48-54.
16. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med 2003; 349: 1414-1422.
17. Sporik R, Ingram JM, Price W, Sussman JH, Honsinger RW, Platts-Mills TA. Association of asthma with serum IgE and skin test reactivity to allergens among children living at high altitude. Tickling the dragon's breath. Am J Respir Crit Care Med 1995; 151: 1388-1392.
18. Charpin D, Birnbaum J, Haddi E, et al. Altitude and allergy to house-dust mites. A paradigm of the influence of environmental exposure on allergic sensitization. Am Rev Respir Dis. 1991; 143: 983-986.
19. Gern JE, Reardon CL, Hoffjan S, et al. Effects of dog ownership and genotype on immune development and atopy in infancy. J Allergy Clin Immunol 2004; 113: 307-314.
20. Celedón JC, Litonjua AA, Ryan L, Platts-Mills T, Weiss ST, Gold DR. Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life. Lancet 2002; 360: 78.
21. Braun-Fahrländer C. Environmental exposure to endotoxin and other microbial products and the decreased risk of childhood atopy: evaluating developments since April 2002. Curr Opin Allergy Clin Immunol 2003; 3: 325-329.
22. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501-1507.
23. Gern JE, Busse WW. Relationship of viral infections to wheezing illnesses and asthma. Nat Rev Immunol 2002; 2: 132-138.
24. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354: 541-545.
25. de Meer G, Janssen NA, Brunekreef B. Early childhood environment related to microbial exposure and the occurrence of atopic disease at school age. Allergy 2005; 60: 619-625.
26. Dykewicz MS. Occupational asthma: current concepts in pathogen-esis, diagnosis, and management. J Allergy Clin Immunol 2009; 123: 519-528.
27. Malo JL, Lemière C, Gautrin D, Labrecque M. Occupational asthma. Curr Opin Pulm Med 2004; 10: 57-61.
28. Venables KM, Chan-Yeung M. Occupational asthma. Lancet 1997; 349: 1465-1469.
29. Sastre J, Vandenplas O, Park HS. Pathogenesis of occupational asthma. Eur Respir J 2003; 22: 364-373.
30. Tager IB. The effects of second-hand and direct exposure to tobacco smoke on asthma and lung function in adolescence. Paediatr Respir Rev 2008; 9: 29-37.
31. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled cortico-steroid treatment in mild asthma. Thorax 2002; 57: 226-230.
32. Nafstad P, Kongerud J, Botten G, Hagen JA, Jaakkola JJ. The role of passive smoking in the development of bronchial obstruction during the first 2 years of life. Epidemiology 1997; 8: 293-297.
33. Kim H, Bernstein JA. Air pollution and allergic disease. Curr Allergy Asthma Rep 2009; 9: 128-133.
34. Belanger K, Triche EW. Indoor combustion and asthma. Immunol Allergy Clin North Am 2008; 28: 507-519.
35. Gauderman WJ, Avol E, Gilliland F, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 2004; 351: 1057-1067.
36. Devereux G, Seaton A. Diet as a risk factor for atopy and asthma. J Allergy Clin Immunol 2005; 115: 1109-1117.
37. Friedman NJ, Zeiger RS. The role of breast-feeding in the development of allergies and asthma. J Allergy Clin Immunol 2005; 115: 1238-1248.
38. Faniran AO, Peat JK, Woolcock AJ. Prevalence of atopy, asthma symptoms and diagnosis, and the management of asthma: comparison of an affluent and a non-affluent country. Thorax 1999; 54: 606-610.
39. Roth M, Black JL. An imbalance in C/EBPs and increased mitochondrial activity in asthmatic airway smooth muscle cells: novel targets in asthma therapy? Br J Pharmacol 2009; 157: 334-341.
40. Oryszczyn MP, Bouzigon E, Maccario J, et al. Interrelationships of quantitative asthma-related phenotypes in the Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsive-ness, and Atopy. J Allergy Clin Immunol 2007; 119: 57-63.
41. Kaur D, Saunders R, Berger P, et al. Airway smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth muscle migration in asthma. Am J Respir Crit Care Med 2006; 174: 1179-1188.
42. Sutcliffe A, Kaur D, Page S, et al. Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics. Thorax 2006; 61: 657-662.
43. Woodman L, Sutcliffe A, Kaur D, et al. Chemokine concentrations and mast cell chemotactic activity in BAL fluid in patients with eosinophilic bronchitis and asthma, and in normal control subjects. Chest 2006; 130: 371-378.
44. Scott K, Bradding P. Human mast cell chemokines receptors: implications for mast cell tissue localization in asthma. Clin Exp Allergy 2005; 35: 693-697.
45. Schmidlin F, Amadesi S, Vidil R, et al. Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle. Am J Respir Crit Care Med 2001; 164: 1276-1281.
46. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806-817.
47. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140: 1745-1753.
48. Bucchieri F, Puddicombe SM, Lordan JL, et al. Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am J Respir Cell Mol Biol 2002; 27: 179-185.
49. Kicic A, Sutanto EN, Stevens PT, Knigh, DA, Stick SM. Intrinsic biochemical and functional differences in bronchial epithelial cells of children with asthma. Am J Respir Crit Care Med 2006; 174: 1110-1118.
50. Barbato A, Turato G, Baraldo S, et al. Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med 2006; 174: 975-981.
51. Puddicombe SM, Polosa R, Richter A, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14: 1362-1374
52. Huang J, Olivenstein R, Tah, R, Hamid Q, Ludwig M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. Am J Respir Crit Care Med 1999; 160: 725-729.
53. Vignola AM, Kips J, Bousquet J. Tissue remodeling as a feature of persistent asthma. J Allergy Clin Immunol 2000; 105: 1041-1053.
54. Akers IA, Parsons M, Hill MR, et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Cell Mol Physiol 2000; 278: L193-L201.
55. Ebina M, Takahashi T, Chiba T, Motomiya M. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis 1993; 148: 720-726.
56. Huber H, Koesser K. The pathology of bronchial asthma. Arch Intern Med 1922; 30: 689-760.
57. Cutz E, Levison H, Cooper DM. Ultrastructure of airways in children with asthma. Histopathology 1978; 2: 407-421.
58. Cokugras H, Akcakaya N, Seckin I, Camcioglu Y, Sarimurat N, Aksoy F. Ultrastructural examination of bronchial biopsy specimens from children with moderate asthma. Thorax 2001; 56: 25-29.
59. Jeffery P. Inflammation and remodeling in the adult and child with asthma. Pediatr Pulmonol 2001; 21: 3-16.
60. McKay KO, Hogg JC. The contribution of airway structure to early childhood asthma. Med J Aust 2002; 177: S45-S47.
61. Jenkins HA, Cool C, Szefler SJ, et al. Histopathology of severe childhood asthma: a case series. Chest 2003; 124: 32-41.
62. Payne DN, Rogers AV, Adelroth E, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003; 167: 78-82.
63. Avdalovic M, Gershwin LJ, Joad JP, et al. Asthma/allergic airways disease: does postnatal exposure to environmental toxicants promote airway pathobiology? Toxicol Pathol 2007; 35: 97-110.
64. Borger P, Tamm M, Black JL, Roth M. Asthma: is it due to an abnormal airway smooth muscle cell? Am J Respir Crit Care Med 2006; 174: 367-372.
65. Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, Kay AB. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax 1997; 52: 447-452.
66. Khan LN, Kon OM, Macfarlane AJ, et al. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am J Respir Crit Care Med 2000; 162: 1377-1382.
67. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophilic airway hyper-responsiveness and the late asthmatic response. Lancet 2000; 356: 2144-2148.
68. McCallister JW. Reslizumab and eosinophilic asthma: one step closer to phenotype-directed therapy? Am J Respir Crit Care Med 2011; 184(10): 1096-1097
69. Cox G, Thomson NC, Rubin AS, et al. Asthma Control during the Year after Bronchial Thermoplasty. N Engl J Med 2007; 356: 1327-1337.
70. Hakonarson H, Grunstein MM. Autocrine regulation of airway smooth muscle responsiveness. Respir Physiol Neurobiol 2003; 137: 263-276.
71. McKay S, Sharma HS. Autocrine regulation of asthmatic airway inflammation: role of the airway smooth muscle. Respir Res 2002; 3: 11.
72. Kahan BD. Cyclosporine. N Engl J Med 1989; 321.
73. Sano T, Nakamura Y, Matsunaga Y, et al. FK506 and cyclosporin A inhibit granulocyte/macrophage colony-stimulating factor production by mononuclear cells in asthma. Eur Respir J 1995; 8: 1473-1478.
74. Faffe DS, Whitehead T, Moore PE, et al. IL-13 and IL-4 promote TARC release in human airway smooth muscle cells: role for IL-4 genotype. Am J Physiol Lung Cell Mol Physiol 2003; 285: L907.
75. Johnson PR, Roth M, Tamm M, et al. Airway smooth muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med 2001; 164: 474-477.
76. Burgess JK, Carlin S, Pack RA, et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J Allergy Clin Immunol 2004; 113: 683-689.
77. Borger P, Miglino N, Baraket M, Black JL, Tamm M, Roth M. Impaired translation of CCAAT/enhancer binding protein alpha mRNA in bronchial smooth muscle cells of asthmatic patients. J Allergy Clin Immunol 2009; 123: 639-645.
78. Global Initiative for COPD. Gold report 2008. http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2005.
79. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
80. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-1243.
81. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
82. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
83. Fullerton DG, Bruce N, Gordon S. Indoor air pollution from biomass fuel smoke is a major health concern in the developing world. Trans R Soc Trop Med Hyg 2008; 102(9): 843-851.
84. Mayer AS, Newman LS. Genetic and environmental modulation of chronic obstructive pulmonary disease. Respir Physiol 2001; 128: 3-11.
85. Givelber RJ, Couropmitree NN, Gottlieb DJ, et al. Segregation analysis of pulmonary function among families in the Framingham Study. Am J Respir Crit Care Med 1998; 157: 1445-1451.
86. Redline S, Tishler PV, Lewitter FI, Tager IB, Munoz A, Speizer FE. Assessment of genetic and nongenetic influences on pulmonary function. A twin study. Am Rev Respir Dis 1987; 135: 217-222.
87. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365(9478): 2225-2236.
88. C. GSTM1 and GSTT1 null alleles are risk factors for excess lung function decline: a longitudinalcohort study of the general population. Genetics of lung function decline and COPD development. Thesis University of Groningen. Gildeprint, Enschede 2007, 125-135. ISBN: 978-90-367-3329-3328,
89. Gosman MME, Boezen HM, Van Diemen CC, et al. A disintegrin and metalloprotease 33 and chronic obstructive pulmonary disease pathophysiology. Thorax 2007; 62: 242-247.
90. Van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Nolte IM, Boezen HM. Decorin and TGF-p\ polymorphisms and development of COPD in a general population. Respir Res 2006; 7: 89.
91. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 462-469.
92. Blanc PD, Eisner MD, Earnest G, et al. Further exploration of the links between occupational exposure and chronic obstructive pulmonary disease. J Occup Environ Med 2009; 51: 804-810.
93. Matheson MC, Benke G, Raven J, et al. Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease. Thorax 2005; 60: 645-651.
94. Hnizdo E, Sullivan PA, Bang KM, Wagner G Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2002; 156: 738-746.
95. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
96. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991; 303: 671-675.
97. Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994; 149: 616-619.
98. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J 1999; 13: 1109-1114.
99. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126: 59-65.
100. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
101. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998; 158: 1277-1285.
102. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Alveolar Med 2003; 167: 418-424.
103. Barnes P. Alveolar macrophages as orchestrators of COPD. J COPD 2004; 1: 59-70.
104. Saetta M, Baraldo S, Corbino L. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717.
105. Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 380-386.
106. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000; 117: 10S-14S.
107. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309.
108. Plantier L, Boczkowski J, Crestani B. Defect of alveolar regeneration in pulmonary emphysema: role of lung fibroblasts. Int J Chron Obstruct Pulmon Dis 2007; 2: 463-469.
109. Togo S, Holz O, Liu X, et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med 2008; 178: 248-260.
110. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968; 278: 1355-1360.
111. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298: 1277-1281.
112. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291: 755-758.
113. Gelb AF, Hogg JC, Müller NL, et al. Contribution of emphysema and small airways in COPD. Chest 1996; 109: 353-359.
114. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
115. De Boer WI, van Schadewijk A, Sont JK, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1951-1957.
116. Takizawa H, Tanaka M, Takami K, et al. Increased Expression of Transforming Growth Factor-beta 1 in Small Airway Epithelium from Tobacco Smokers and Patients with Chronic Obstructive Pulmonary Disease (COPD). Am J Respir Crit Care Med 2001; 163: 1476-1483.
117. Ihn H. Pathogenesis of fibrosis: role of TGF-b & CTGF. Curr Opin Rheumatol 2002; 14: 681-685.
118. Chen G, Grotendorst G, Eichholtz T, Khalil N. GM-CSF increases airway smooth muscle cell connective tissue expression by inducing TGF-beta receptors. Am J Physiol Lung Cell Mol Physiol 2003; 284: L548-L556.
119. Saetta M, Ghezzo H, Kim WD, et al. Loss of alveolar attachments in smokers: an early morphometric correlate of lung function impairment. Am Rev Respir Dis 1985; 132: 894-900.
120. Daheshia M. Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Curr Med Res Opin 2005; 21: 587-594.
121. Srivastava PK, Dastidar SG, Ray A. Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy. Expert Opin Investig Drugs 2007; 16: 1069-1078.
122. Demedts IK, Morel-Montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 2006; 61: 196-201.
123. Hoshino Y, Mio T, Nagai S, Miki H, Ito I, Izumi T. Cytotoxic effects of cigarette smoke extract on an alveolar type II cell-derived cell line. Am J Physiol: Lung Cell Mol Physiol 2001; 281: 509-516.
124. Ishii T, Matsuse T, Igarashi H, Masuda M, Teramoto S, Ouchi, Y. Tobacco smoke reduces viability in human lung fibroblasts: Protective effect of glutathione S-transferase P1. Am J Physiol: Lung Cell Mol Physiol 2001; 280: 1189-1195.
125. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207.
126. Bernhard D, Huck CW, Jakschitz T, et al. Development and evaluation of an in vitro model for the analysis of cigarette smoke effects on cultured cells and tissues. J Pharmacol Toxicol Methods 2004; 50: 45-51.
127. Rennard SI, Togo S, Holz O. Cigarette smoke inhibits alveolar repair: a mechanism for the development of emphysema. Proc Am Thorac Soc 2006; 3: 703-708.
128. Sato E, Koyama S, Takamizawa A, et al. Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities. Am J Physiol 1999; 277: L1149-L1157.
129. Tuder RM, Voelkel NF. Pathology of chronic bronchitis and emphysema. In: Voelkel NF, MacNee W, Eds. Chronic Obstructive Lung Disease. Montreal, Canada: Dekker 2001; pp. 90-113.
130. Wright JL, Hobson J, Wiggs BR, Hogg JC. Comparison of inflammatory cells in bronchoalveolar fluid with those in the lumen and tissue peripheral airways and alveolar airspace. Lung 1988; 166: 75-83.
131. MacNee W, Wiggs B, Belzberg AS, Hogg JC. The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med 1989; 321: 924-928.
132. Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003; 167: 1083-1089.
133. Gessner C, Scheibe R, Wotzel M, et al. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respir Med 2005; 99: 1229-1240.
134. Kubo S, Kobayashi M, Masunaga Y, et al. Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs. Eur Respir J 2005; 26: 993-1001.
135. Fujita M, Shannon JM, Irvin CG, et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 280: L39-L49.
136. Churg A, Wang RD, Tai H, Wang XS, Xie CS, Wright JL. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004; 170: 492-498.
137. Gensch E, Gallup M, Sucher A, et al. Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem 2004; 279: 39085-39093.
138. Landschulz WH, Johnson PF, Adashi EY, Graves BJ, McKnight SL. Isolation of a recombinant copy of the gene encoding C/EBP. Genes Dev 1988; 2: 786-800.
139. Graves BJ, Johnson PF, McKnight SL. Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene. Cell 1986; 44: 565-576.
140. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 2007; 17: 318-324.
141. Rosen ED, Hsu CH, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002; 16: 22-26.
142. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 2002; 365: 561-575.
143. Birkenmeier EH, Gwynn B, Howard S, et al. Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 1989; 3: 1146-1156.
144. Hendricks-Taylor LR, Darlington GJ. Inhibition of cell proliferation by C/EBP alpha occurs in many cell types, does not require the presence of p53 or Rb, and is not affected by large T-antigen. Nucleic Acids Res 1995; 23: 4726-4733.
145. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 2005; 118: 2545-2555.
146. Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 1991; 251: 288-292.
147. Lasa A, Carnicer MJ, Aventín A, et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia 2004; 18: 1231-1237.
148. Helbling D, Mueller BU, Timchenko NA, et al. The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin. Proc Natl Acad Sci USA 2004; 101: 13312-13317.
149. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009; 27: 619-628.
150. Timchenko NA, Wilde M, Nakanishi M, Smith JR, Darlington GJ. CCAAT/enhancer-binding protein {alpha} (C/EBP{alpha}) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev 1996; 10: 804-815.
151. Rüdiger JJ, Roth M, Bihl MP, et al. Interaction of C/EBP{alpha} and the glucocorticoid receptor in vivo and in non-transformed human cells. FASEB J 2002; 16: 177-184.
152. Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-1299.
153. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010.
154. Muller C, Alunni-Fabbroni M, Kowenz-Leutz, E, Mo X, Tomma-sino M, Leutz A. Separation of C/EBPalpha-mediated proliferation arrest and differentiation pathways. Proc Natl Acad Sci USA 1999; 96: 7276-7281.
155. Calkhoven CF, Müller C, Leutz A. Translational control of C/EBP alpha and C/EBPbeta isoform expression. Genes Dev 2000; 14: 1920-1932.
156. Ossipow V, Descombes P, Schibler U. CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci USA 1993; 90: 8219-8223.
157. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991; 67: 69-79.
158. Calkhoven CF, Snippe L, Ab G. Differential stimulation by CCAAT/enhancer-binding protein alpha isoforms of the estrogen-activated promoter of the very-low-density apolipoprotein II gene, Eur J Biochem 1997; 249: 113-120.
159. Raught B, Gingras AC, James A, Medina D, Sonenberg N, Rosen JM. Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 1996; 56: 4382-4386.
160. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-8148.
161. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990; 62: 379-390.
162. Dever TE. Gene-specific regulation by general translation factors. Cell 2002; 108: 545-556.
163. Lawrence JC Jr, Abraham RT. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation. Trends Biochem Sci 1997; 22: 345-349.
164. Lin TA, Kong X, Haystead TA, et al. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 1994; 266: 653-656.
165. Pause A, Belsham GJ, Gingras AC, et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 1994; 371: 762-767.
166. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277: 99-101.
167. Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 1999; 96: 4438-4442.
168. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68: 913-963.
169. Mathews MB, Sonenberg N, Hershey JWB. Translational Control of Gene Expression. Cold Spring Harbor: Laboratory Press 2000; pp 467-486.
170. Wiesenthal V, Leutz A, Calkhoven CF. Analysis of translation initiation using a translation control reporter system. Nat Protoc 2006; 1: 1531-1537.
171. Wiesenthal V, Leutz A, Calkhoven CF. A translation control reporter system (TCRS) for the analysis of translationally controlled processes in the vertebrate cell. Nucleic Acids Res 2006; 34: e23.
172. Pöyry TA, Kaminski A, Jackson RJ. What determines whether mammalian ribosomes resume scanning after translation of a short upstream open reading frame? Genes Dev 2004; 18: 62-75.
173. Calkhoven CF, Muller C, Martin R, Krosl G, Pietsch H, Hoang T, Leutz A. Translational control of SCL-isoform expression in hematopoietic lineage choice. Genes Dev 2003; 17: 959-964.
174. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000; 6: 1099-1108.
175. Cazzola M, Skoda RC, Translational pathophysiology: a novel molecular mechanism of human disease. Blood 2000; 95: 3280-3288.
176. Polymenis M, Schmidt EV. Coupling of cell division to cell growth by translational control of the G1 cyclin CLN3 in yeast. Genes Dev 1997; 11: 2522-2531.
177. Rogers GW Jr, Edelman GM, Mauro VP. Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc Natl Acad Sci USA 2004; 101: 2794-2799.
178. Timchenko LT, Iakova P, Welm AL, Cai ZJ, Timchenko NA. Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol Cell Biol 2002; 22: 7242-7257.
179. Helbling D, Mueller BU, Timchenko NA, et al. CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16). Blood 2005; 106: 1369-1375.
180. Kawagishi H, Wakoh T, Uno H, et al. Hzf regulates adipogenesis through translational control of C/EBPalpha. EMBO J 2008; 27: 1481-1490.
181. Mathews MB, Sonenberg N, Hershey JWB Translational Control of Gene Expressio. Cold Spring Harbor: Laboratory Press: USA 2000; pp 1-31.
182. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, Sabatini DD, Ron D. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001; 7: 1153-1163.
183. Scheuner D, Song B, McEwen E, et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001; 7: 1165-1176.
184. Delépine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-a kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000; 25: 406-409.
185. Leegwater PA, Vermeulen G, Könst AA, et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalo-pathy with vanishing white matter. Nat. Genet 2001; 29: 383-388.
186. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990; 345: 544-547.
187. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18: 2507-2517.
188. Anthony B, Carter P, De Benedetti A. Overexpression of the proto-oncogene/ translation factor 4E in breast-carcinoma cell lines. Int J Cancer 1996; 65: 858-863.
189. DeFatta RJ, Turbat-Herrera EA, Li BD, Anderson W, De Benedetti A. Elevated expression of eIF4E in confined early breast cancer lesions: possible role of hypoxia. Int J Cancer 1999; 80: 516-522.
190. Wang S, Rosenwald IB, Hutzler MJ, et al. Expression of the eukaryotic translation initiation factors 4E and 2a in non-Hodgkin's lymphomas. Am J Pathol 1999; 155: 247-255.
191. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000; 82: 161-166.
192. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPa expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
193. Rask K, Thörn M, Pontén F, et al. Increased expression of the transcription factors CCAAT-enhancer binding protein-p (C/EBPp) and C/EBP (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 2000; 86: 337-343.
194. Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y, Firestone GL. Role of the CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells. J Biol Chem 1998; 273: 2008-2014.
195. Cha HH, Cram EJ, Wang EC, Huang AJ, Kasler HG, Firestone GL. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells. J Biol Chem 1998; 273: 1998-2007.
196. Borger P, Matsumoto H, Boustany S, et al. Disease-specific expression and regulation of CCAAT/enhancer-binding proteins in asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2007; 119: 98-105.
197. Miglino N, Roth M, Tamm M, Borger P. House dust mite extract down-regulates C/EBPalpha in asthmatic bronchial smooth muscle cells. Eur Respir J 2011; 38: 50-58.
198. Plopper CG, Smiley-Jewell SM, Miller LA, et al. Asthma/allergic airways disease: does postnatal exposure to environmental toxicants promote airway pathobiology? Toxicol Pathol 2007; 35: 97-110.
199. Ma X, Cheng Z, Kong H, et al. Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1181-L1189.
200. Stephens NL, Li W, Jiang H, Unruh H, Ma X. The biophysics of asthmatic airway smooth muscle. Respir Physiol Neurobiol 2003; 137: 125-140.
201. Shore SA. Airway smooth muscle in asthma: not just more of the same. N Engl J Med 2004; 351: 531-532.
202. Sekiya T, Tsunemi Y, Miyamasu M, et al. Variations in the human Th2-specific chemokine TARC gene. Immunogenetics 2003; 54: 742-745.
203. Borger P, Black JL, Roth M. Asthma and the CCAAT-enhancer binding proteins: a holistic view on airway inflammation and remodelling. J Allergy Clin Immunol 2002; 110: 841-846.
204. Lin SJ, Shu PY, Chang C, Ng AK, Hu CP. IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma line Hep38. J Immunol 2003; 171: 4708-4716.
205. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146: 108-113.
206. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem 2002; 277: 6923-6928.
207. Didon L, Qvarford I, Andersson O, Nord M, Riise GC. Decreased CCAAT/enhancer binding protein transcription factor activity in chronic bronchitis and COPD. Chest 2005; 127: 1341-1346.
208. Borger P, Koëter GH, Timmerman JAB, Vellenga E, Tomee JFC, Kauffman HF. Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis 1999; 180: 1267-1274.
209. Kuang PP, Goldstein RH. Regulation of elastin gene transcription by interleukin-1 beta-induced C/EBP beta isoforms. Am J Physiol Cell Physiol 2003; 285: C1349-C1355.
210. Shim M, Smart RC. Lithium stabilizes the CCAAT/enhancer-binding protein alpha (C/EBPalpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity. J Biol Chem 2003; 278(22): 19674-19681.